Free Trial

Sangamo Therapeutics (NASDAQ:SGMO) Rating Lowered to Hold at StockNews.com

Sangamo Therapeutics logo with Medical background

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) was downgraded by investment analysts at StockNews.com from a "buy" rating to a "hold" rating in a report released on Tuesday.

Several other analysts also recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research report on Thursday, December 19th. Barclays raised their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an "overweight" rating in a research note on Thursday, November 14th. Finally, Truist Financial raised shares of Sangamo Therapeutics from a "hold" rating to a "buy" rating and set a $7.00 target price for the company in a research report on Friday, December 13th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $7.00.

View Our Latest Stock Report on Sangamo Therapeutics

Sangamo Therapeutics Stock Performance

Shares of NASDAQ SGMO traded up $0.11 during trading on Tuesday, hitting $2.50. 2,521,419 shares of the company traded hands, compared to its average volume of 6,920,536. The business's fifty day moving average is $2.00 and its 200 day moving average is $1.15. The firm has a market capitalization of $521.62 million, a price-to-earnings ratio of -3.33 and a beta of 1.15. Sangamo Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The business had revenue of $49.41 million for the quarter, compared to the consensus estimate of $26.55 million. During the same period in the prior year, the business earned ($0.34) EPS. On average, analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its holdings in shares of Sangamo Therapeutics by 58.8% in the second quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company's stock valued at $1,479,000 after purchasing an additional 1,528,600 shares during the last quarter. Marshall Wace LLP increased its stake in Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company's stock valued at $207,000 after buying an additional 207,476 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Sangamo Therapeutics during the 2nd quarter worth approximately $67,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Sangamo Therapeutics during the 2nd quarter worth approximately $89,000. Finally, Vontobel Holding Ltd. boosted its stake in shares of Sangamo Therapeutics by 412.3% in the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company's stock worth $259,000 after buying an additional 241,440 shares during the last quarter. 56.93% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Company Profile

(Get Free Report)

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

Featured Stories

Should You Invest $1,000 in Sangamo Therapeutics Right Now?

Before you consider Sangamo Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sangamo Therapeutics wasn't on the list.

While Sangamo Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines